Bromelain-based enzyme injection - MediWound

Drug Profile

Bromelain-based enzyme injection - MediWound

Alternative Names: IBS; Injectable bromelain solution - MediWound; MWPC 003

Latest Information Update: 02 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediWound
  • Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Connective tissue disorders

Most Recent Events

  • 20 Dec 2016 MediWound has patent protection for Bromelain-based enzyme injection in USA
  • 31 May 2016 Preclinical trials in Connective tissue disorders in Israel (Parenteral) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top